BI 836826

Drug Profile

BI 836826

Alternative Names: BI-836826

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Jan 2018 Boehringer Ingelheim withdraws a phase I trial prior to enrolment due to company decision for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) (IV)(NCT03343678)
  • 03 Jan 2018 Boehringer Ingelheim completes a phase I trial in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in South Korea, France and Germany (IV) (NCT01403948)
  • 23 Nov 2017 Boehringer Ingelheim plans a phase I trial for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in December 2017 (NCT03343678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top